Bionano Genomics

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.

News

Penny Stocks

Movers

BNGO

Bionano Genomics, Inc. (NASDAQ: BNGO) shares are trading lower Monday. The company&#39;s stock began trading on a reverse split-adjusted basis on Monday.

What&#39;s Going On With Bionano Genomics Stock?

Long Ideas

Small Cap

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

BLIN

The Dow Jones closed lower by over 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Over $1M Bet On Bioventus? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

Short Ideas

Health Care

General

ACET

CUTR

NVAX

NVTA

SAVA

STOK

VTGN

SENS

As of the close of business on Wednesday, 6/7, we captured the Top 10 Highest Short Interest % stocks within the Healthcare sector.

The average short interest for stocks within the Healthcare sector stands at 3.5%. Therefore, the below stocks are showing a more pessimistic outlook than their peers within the respective sector.

Short Interest Sector Focus: Healthcare Sector

Bionano Genomics Inc

Press Releases

Study Using OGM in Neural Tube Defects Reveals Previously Unreported Variants and Candidate Genes with Potential Links to the Devastating Birth Defect

Earnings

Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025

Bionano Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGM

Bionano Announces Publication Showing OGM can Provide an Accurate and Cost-Effective Solution for Sizing Large Repeat Expansions in Constitutional Genetic Disease

International Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood Cancers

Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025

Bionano Laboratories Announces Publication of the Largest Study To-Date Evaluating Clinical Utility of Optical Genome Mapping Across Multiple Hematologic Malignancies

Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress

Bionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic Disorders

Bionano Recaps Global Momentum Behind Optical Genome Mapping at the 2025 Annual Meeting of the European Society of Human Genetics Held Recently in Milan, Italy

Comments

Bionano Genomics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell